Literature DB >> 22955427

Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study.

Takeshi Nishijima1, Hirokazu Komatsu, Koichiro Higasa, Misao Takano, Kiyoto Tsuchiya, Tsunefusa Hayashida, Shinichi Oka, Hiroyuki Gatanaga.   

Abstract

BACKGROUND: Tenofovir is a widely used antiretroviral drug although it can cause kidney tubular dysfunction (KTD). The aim of this study was to determine the association between polymorphisms in genes encoding drug transporters and KTD in Japanese patients treated with tenofovir.
METHODS: The association between tenofovir-induced KTD and 14 single nucleotide polymorphisms (SNPs) in the ABCC2, ABCC4, ABCC10, SCL22A6, and ABCB1 genes was investigated in 190 Japanese patients. KTD was diagnosed by the presence of at least 3 abnormalities in the following parameters: fractional tubular resorption of phosphate, fractional excretion of uric acid, urinary β2-microglobulin, urinary α1-microglobulin, and urinary N-acetyl-β-D-glucosaminidase. Genotyping was performed by allelic discrimination using TaqMan 5'-nuclease assays with standard protocols. Associations between genotypes and KTD were tested by univariate and multivariate logistic regression analyses.
RESULTS: KTD was diagnosed in 19 of the 190 (10%) patients. Univariate and multivariate analyses showed a significant association between KTD and genotype CC at position -24 CC (adjusted odds ratio [OR], 20.08; 95% confidence interval [CI], 1.711-235.7; P= .017) and genotype AA at position 1249 (adjusted OR, 16.21; 95% CI, 1.630-161.1; P= .017) of ABCC2. Multivariate analysis showed higher adjusted OR for patients with both homozygotes (adjusted OR, 38.44; 95% CI, 2.051-720.4; P= .015). ABCC2 haplotype -24T and 1249G was a protective haplotype for KTD (OR, 0.098; 95% CI, .002-.603; P= .003
CONCLUSIONS: This is the first study of our knowledge to identify the association between SNPs in ABCC2 and tenofovir-induced KTD in an Asian population. Close monitoring of renal function is warranted in tenofovir-treated patients with these SNPs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955427     DOI: 10.1093/cid/cis772

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  32 in total

Review 1.  Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Authors:  David W Haas; Philip E Tarr
Journal:  Curr Opin HIV AIDS       Date:  2015-03       Impact factor: 4.283

Review 2.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

3.  Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Authors:  Valentine Wanga; Charles Venuto; Gene D Morse; Edward P Acosta; Eric S Daar; David W Haas; Chun Li; Bryan E Shepherd
Journal:  Pharmacogenet Genomics       Date:  2015-09       Impact factor: 2.089

4.  Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Gregory M Lucas; Michael J Ross; Peter G Stock; Michael G Shlipak; Christina M Wyatt; Samir K Gupta; Mohamed G Atta; Kara K Wools-Kaloustian; Paul A Pham; Leslie A Bruggeman; Jeffrey L Lennox; Patricio E Ray; Robert C Kalayjian
Journal:  Clin Infect Dis       Date:  2014-09-17       Impact factor: 9.079

Review 5.  Tenofovir nephrotoxicity among Asians living with HIV: review of the literature.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Shinichi Oka
Journal:  Glob Health Med       Date:  2019-12-31

6.  Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.

Authors:  S M Baxi; R M Greenblatt; P Bacchetti; M Cohen; J A DeHovitz; K Anastos; S J Gange; M A Young; B E Aouizerat
Journal:  Pharmacogenomics J       Date:  2017-05-02       Impact factor: 3.550

7.  Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11.

Authors:  Wisith Tun-Yhong; Chatchai Chinpaisal; Perayot Pamonsinlapatham; Sindchai Kaewkitichai
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

8.  Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B.

Authors:  Motohiro Shimizu; Norihiro Furusyo; Hiroaki Ikezaki; Eiichi Ogawa; Takeo Hayashi; Takeshi Ihara; Yuji Harada; Kazuhiro Toyoda; Masayuki Murata; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

9.  A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.

Authors:  Amber Dahlin; Matthias Wittwer; Melanie de la Cruz; Jonathan M Woo; Rujuta Bam; Valeska Scharen-Guivel; John Flaherty; Adrian S Ray; Tomas Cihlar; Samir K Gupta; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

10.  Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines.

Authors:  A Calcagno; J Cusato; L Marinaro; L Trentini; C Alcantarini; M Mussa; M Simiele; A D'Avolio; G Di Perri; S Bonora
Journal:  Pharmacogenomics J       Date:  2015-10-06       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.